Who are in the management team of TTK Healthcare?

As of March 2023, TTK Healthcare's management team includes T T Raghunathan (Executive Chairman), S Kalyanaraman (Whole Time Director), and several non-executive directors, ensuring a diverse governance structure.

As of March 2023, the management team of TTK Healthcare includes:<BR><BR>1. T T Raghunathan - Executive Chairman<BR>2. R K Tulshan - Non-Executive & Non-Independent Director<BR>3. K Shankaran - Non-Executive & Non-Independent Director<BR>4. S Kalyanaraman - Whole Time Director & Secretary<BR>5. Vandana R Walvekar - Non-Executive & Independent Director<BR>6. Girish Rao - Non-Executive & Independent Director<BR>7. S Balasubramanian - Non-Executive & Independent Director<BR>8. N Ramesh Rajan - Non-Executive & Independent Director<BR>9. V Ranganathan - Non-Executive & Independent Director<BR>10. T T Mukund - Director<BR><BR>This team comprises a mix of executive and non-executive members, with various designations contributing to the governance of the company.

When is the next results date for TTK Healthcare?

No Upcoming Board Meetings

What does TTK Healthcare do?

TTK Healthcare Ltd. operates in pharmaceuticals, consumer products, medical devices, and foods. As of March 2025, it reported net sales of ₹190 Cr and a net profit of ₹16 Cr, with a market cap of ₹1,735 Cr.

Overview:<BR>TTK Healthcare Ltd. operates in the diversified industry, focusing on pharmaceuticals, consumer products, medical devices, foods, and protective devices.<BR><BR>History:<BR>Incorporated in May 1958 as Orient Pharma, the company was renamed TTK Pharma in November 1981. The latest quarterly results reported net sales and profit for March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 190 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 16 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 1,735 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 25.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.81% <BR>Debt-Equity: -0.72 <BR>Return on Equity: 6.64% <BR>Price to Book: 1.64 <BR><BR>Contact Details:<BR>Address: 6 Cathedral Road, Chennai Tamil Nadu: 600086 <BR>Tel: 91-44-28116106-28116110 <BR>Email: info@ttkhealthcare.com <BR>Website: http://www.ttkhealthcare.com

Has TTK Healthcare declared dividend?

TTK Healthcare Ltd. has declared a 100% dividend, amounting to ₹10 per share, with an ex-date of July 16, 2024. While the recent total returns show declines in the short term, the company has experienced significant growth over the longer term.

TTK Healthcare Ltd. has declared a 100% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 100%<BR>- Amount per share: 10<BR>- Ex-date: 16 Jul 24<BR><BR>Dividend Yield: 0.81%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -21.3%, the dividend return was 0%, resulting in a total return of -21.3%.<BR><BR>Over the past year, the price return was -14.86%, the dividend return was 0.66%, leading to a total return of -14.2%.<BR><BR>In the 2-year period, the price return was -3.25%, the dividend return was 1.58%, culminating in a total return of -1.67%.<BR><BR>For the 3-year period, the price return was 66.56%, the dividend return was 4.22%, resulting in a total return of 70.78%.<BR><BR>In the last 4 years, the price return was 81.28%, the dividend return was 5.44%, which brought the total return to 86.72%.<BR><BR>Over the past 5 years, the price return was 187.39%, the dividend return was 8.95%, leading to a total return of 196.34%.<BR><BR>Overall, TTK Healthcare has declared a substantial dividend, but the recent total returns indicate a mixed performance, with significant growth over the longer term despite recent declines in shorter periods.

Who are the peers of the TTK Healthcare?

TTK Healthcare's peers include Adani Enterprises, Godrej Industries, and 3M India, among others. TTK Healthcare has average management risk, below average growth, and a 1-year return of -17.61%, outperforming only Adani Enterprises.

Peers: The peers of TTK Healthcare are Adani Enterp., Godrej Industrie, 3M India, DCM Shriram, Swan Energy, Dhunseri Vent., Empire Inds., Krypton Industri, KCK Industries, and Aspinwall & Co.<BR><BR>Quality Snapshot: Excellent management risk is observed at 3M India, while Below Average management risk is found at Adani Enterp., Godrej Industrie, and Krypton Industri, and the rest. Average management risk is present at DCM Shriram, Swan Energy, TTK Healthcare, Dhunseri Vent., Empire Inds., and Aspinwall & Co. Growth is Excellent at Adani Enterp., Good at Godrej Industrie and KCK Industries, while Average growth is seen at DCM Shriram, Dhunseri Vent., and Aspinwall & Co., and the rest. Below Average growth is noted at 3M India, Swan Energy, TTK Healthcare, Empire Inds., and Krypton Industri. Capital Structure is Excellent at 3M India and TTK Healthcare, Good at Dhunseri Vent., and Average at DCM Shriram, Aspinwall & Co., while Below Average is found at Adani Enterp., Godrej Industrie, Swan Energy, Empire Inds., Krypton Industri, and KCK Industries.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Godrej Industrie at 53.06%, while the peer with the lowest is Adani Enterp. at -31.83%. TTK Healthcare's 1-year return is -17.61%, which is better than Adani Enterp. but worse than all other peers. Additionally, peers with negative six-month returns include Swan Energy, Krypton Industri, and TTK Healthcare.

Who are the top shareholders of the TTK Healthcare?

The top shareholders of TTK Healthcare are primarily its promoters, with T T Krishnamachari & Co. holding 67.46%. Other notable shareholders include Jupiter India Fund at 1.52% and individual investors with a combined 16.01%.

The top shareholders of TTK Healthcare are primarily its promoters, with T T Krishnamachari & Co. holding the largest share at 67.46%, represented by its partners Mr. T T Jagannathan and Mr. T T Raghunathan. Other notable shareholders include Jupiter India Fund, which holds 1.52%, and individual investors collectively owning 16.01%. Additionally, there are four mutual fund schemes that hold a combined 0.04%, and nine foreign institutional investors (FIIs) with a total holding of 1.89%.

How big is TTK Healthcare?

As of 24th July, TTK Healthcare Ltd. has a market capitalization of 1,920.00 Cr, with recent Net Sales of 801.49 Cr and a Net Profit of 81.66 Cr. The company has Shareholder's Funds of 1,065.05 Cr and Total Assets of 1,275.24 Cr.

As of 24th July, TTK Healthcare Ltd. has a market capitalization of 1,920.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, TTK Healthcare reported Net Sales of 801.49 Cr and a Net Profit of 81.66 Cr.<BR><BR>For the reporting period of March 2025, the company has Shareholder's Funds amounting to 1,065.05 Cr and Total Assets of 1,275.24 Cr.

Is TTK Healthcare overvalued or undervalued?

As of July 28, 2025, TTK Healthcare is considered undervalued with an attractive valuation grade, a PE ratio of 25.50, and competitive financial metrics, making it a potential buying opportunity despite recent underperformance compared to the Sensex.

As of 28 July 2025, TTK Healthcare's valuation grade has moved from fair to attractive, indicating a positive shift in its market perception. The company is currently considered undervalued, with a PE ratio of 25.50, an EV to EBITDA of 29.89, and a Price to Book Value of 1.69. In comparison to its peers, TTK Healthcare's PE ratio is lower than Sun Pharma's 35.57 and Divi's Lab's 79.83, both of which are categorized as expensive, while it is more favorable than Cipla's attractive PE of 23.53.<BR><BR>TTK Healthcare's financial metrics suggest it is positioned well within its industry, especially with a PEG ratio of 2.04, which is competitive against peers like Dr. Reddy's Labs at 9.35. Despite recent stock performance trailing the Sensex, particularly with a year-to-date return of -9.92% compared to the Sensex's 3.52%, the overall valuation indicates that TTK Healthcare presents a buying opportunity for investors looking for growth in the diversified healthcare sector.

Are TTK Healthcare latest results good or bad?

TTK Healthcare's latest results are mixed; while net profit increased by 18.56% quarter-on-quarter, it declined 3.17% year-on-year, and revenue fell 10.10% from the previous quarter. The company's heavy reliance on non-operating income raises concerns about the sustainability of its earnings, indicating more operational challenges than positives.

TTK Healthcare's latest results present a mixed picture. On one hand, the company reported a net profit of ₹20.39 crores for Q2 FY26, which is an 18.56% increase quarter-on-quarter. However, this figure represents a 3.17% decline year-on-year. <BR><BR>Revenue for the same quarter was ₹203.57 crores, showing a concerning 10.10% decrease from the previous quarter, although it did manage a modest 2.56% growth compared to the same quarter last year. The operating margin, excluding other income, fell sharply to just 2.62%, down from 6.31% in the previous quarter and significantly below the five-year average of 4.2%. <BR><BR>A critical concern is the company's heavy reliance on other income, which constituted 89.25% of profit before tax. This raises questions about the sustainability of earnings derived from core operations. Overall, while the net profit margin has improved, the operational performance is deteriorating, indicating underlying weaknesses that could impact future growth. <BR><BR>In summary, while there are some positive aspects, the overall operational challenges and dependency on non-operating income suggest that the results are more concerning than encouraging.

How has been the historical performance of TTK Healthcare?

TTK Healthcare has shown steady growth in net sales and profit from Mar'21 to Mar'25, with net sales increasing from 636.53 Cr to 801.49 Cr and profit before tax rising from 24.84 Cr to 108.33 Cr. However, the company has faced challenges with rising costs and negative cash flow from operating activities.

Answer:<BR>The historical performance of TTK Healthcare shows a steady growth in net sales and profit over the years, with significant fluctuations in certain metrics.<BR><BR>Breakdown:<BR>TTK Healthcare's net sales have increased from 636.53 Cr in Mar'21 to 801.49 Cr in Mar'25, reflecting a consistent upward trend. Total operating income followed a similar trajectory, rising from 645.77 Cr in Mar'20 to 801.49 Cr in Mar'25. The company faced rising raw material costs, which increased from 98.92 Cr in Mar'21 to 195.34 Cr in Mar'25, while the purchase of finished goods also grew from 148.77 Cr to 186.95 Cr in the same period. Operating profit (PBDIT) showed fluctuations, peaking at 106.07 Cr in Mar'25 after a dip in Mar'22. Profit before tax rose significantly from 24.84 Cr in Mar'22 to 108.33 Cr in Mar'25, leading to a profit after tax of 81.66 Cr in Mar'25, up from 18.51 Cr in Mar'22. The company's total assets increased from 427.04 Cr in Mar'20 to 1,275.24 Cr in Mar'25, while total liabilities also rose, reflecting a growth in both equity capital and reserves. Cash flow from operating activities has been negative in recent years, indicating challenges in cash generation, although cash flow from investing activities remained positive. Overall, TTK Healthcare has demonstrated growth in sales and profitability, despite facing challenges with costs and cash flow management.

Should I buy, sell or hold TTK Healthcare?

Which are the latest news on TTK Healthcare?

Why is TTK Healthcare falling/rising?

As of 03-Dec, TTK Healthcare Ltd. is facing a decline in its stock price, currently at 1,092.00, down 1.22%. The stock has underperformed against the Sensex, trading below moving averages, experiencing decreased investor interest, and showing poor long-term growth, which raises concerns about its valuation and future prospects.

As of 03-Dec, TTK Healthcare Ltd. is experiencing a decline in its stock price, currently at 1,092.00, which represents a change of -13.5 or -1.22%. This downward movement can be attributed to several factors highlighted in the provided data. <BR><BR>Firstly, the stock has underperformed significantly compared to the benchmark Sensex, with a one-week decline of -2.37% against a -0.59% drop in the Sensex, and a year-to-date decrease of -22.92% compared to the Sensex's gain of +8.92%. This trend indicates a consistent underperformance relative to the broader market.<BR><BR>Moreover, TTK Healthcare is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, suggesting a bearish trend. Additionally, there has been a decrease in investor participation, with delivery volume falling by -2.86% against the 5-day average, which may indicate waning interest from investors.<BR><BR>Financially, the company has shown poor long-term growth, with net sales growing at an annual rate of only 7.36% over the last five years. The recent financial results also reflect challenges, as the profit before tax (PBT) has fallen by -58.29%, and a significant portion of the profit is derived from non-operating income, which raises concerns about the sustainability of earnings.<BR><BR>Furthermore, the stock's valuation appears to be at a premium compared to its peers, with a price-to-book value of 1.4, while the return on equity (ROE) stands at a modest 6.5. Despite a profit increase of 9.3% over the past year, the stock has generated a negative return of -23.64%, which may deter potential investors.<BR><BR>Lastly, the minimal stake held by domestic mutual funds, at only 0.01%, suggests a lack of confidence in the stock's current valuation or business prospects. This combination of underperformance, declining investor interest, and financial challenges contributes to the stock's falling price.

Is TTK Healthcare technically bullish or bearish?

As of December 3, 2025, the technical trend has shifted to a moderate bearish stance, driven by bearish MACD readings, Bollinger Bands, and daily moving averages, despite mixed signals from the RSI and KST, with the stock underperforming against the Sensex.

As of 3 December 2025, the technical trend has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include the bearish MACD readings on both the weekly and monthly time frames, bearish Bollinger Bands, and a bearish daily moving average. The RSI shows no signal on the weekly but is bullish on the monthly, indicating mixed signals. The KST is mildly bullish weekly but bearish monthly, while the OBV is mildly bearish weekly and mildly bullish monthly, adding to the overall bearish sentiment. The stock has underperformed significantly against the Sensex over multiple time frames, further supporting the bearish outlook.